ANDA 219145, held by Hikma Pharmaceuticals. Methylprednisolone Acetate.
As of Nov 21, 2026, ANDA 219145 (Methylprednisolone Acetate), held by Hikma Pharmaceuticals, was first approved by FDA on Apr 16, 2025, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 16, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methylprednisolone Acetate80MG/ML · injectable;injection | Methylprednisolone Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters